Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model
Table 1
Modifiable SCORE risk factors at baseline and final (6-week) assessments.
Systolic Blood Pressure (mmHg)
Total Cholesterol (mmol/L)
Comorbidity/Risk Factor*
Baseline
6-week
Absolute Change
Baseline
6-week
Absolute Change
Mean (SD)
Mean (SD)
Mean (SD)
95% CI
Mean (SD)
Mean (SD)
Mean (SD)
95% CI
All Patients ( = 825)
132.0 (14.0)
128.2 (13.7)
3.75 (13.3)
2.84, 4.66
5.60 (1.00)
4.40 (1.00)
1.18 (0.89)
1.12, 1.24
Hypertension ( = 423)
138.6 (13.3)
132.0 (12.9)
6.59 (14.1)
5.25, 7.94
5.51 (0.92)
4.36 (0.98)
1.14 (0.91)
1.05, 1.23
Diabetes ( = 342)
132.7 (13.7)
129.2 (13.9)
3.49 (13.5)
2.06, 4.93
5.63 (1.11)
4.51 (1.08)
1.26 (0.94)
1.16, 1.36
Metabolic Syndrome ( = 395)
136.0 (13.9)
131.7 (13.0)
4.27 (13.9)
2.89, 5.64
5.62 (0.99)
4.35 (1.04)
1.27 (0.97)
1.17, 1.37
Current Smokers ( = 188)
132.1 (14.4)
126.6 (13.6)
5.50 (13.1)
3.62, 7.38
5.67 (1.18)
4.34 (0.92)
1.33 (0.97)
1.47, 1.19
*Patients may have more than one comorbid condition.
